Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesUniversal Ibogaine Inc

Universal Ibogaine Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None CAD 0.00(0%)
Last update at 2026-11-04T21:00:08.927500Z
Market Cap
1.56M

Momentum Score

…

Universal Ibogaine Inc., a life sciences company, develops, acquires, and operates addiction treatment clinics in Canada. The company also undertakes planned clinical trial for research into the use of ibogaine for addiction treatment. Universal Ibogaine Inc. is headquartered in Calgary, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.01
Low
0.04
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Universal Ibogaine Inc is a publicly listed company that appears to develop and provide ibogaine-based therapies and clinic services for substance use disorders. Long-term growth drivers may include rising demand for addiction treatment, clinical and regulatory progress, and expansion of clinic operations, making it a potential exposure to a nascent therapeutic niche. Key risks include regulatory and clinical uncertainty, unproven efficacy, operational and legal challenges across jurisdictions, limited public disclosure and likely need for additional financing.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.01
Dividend Yield
-
Revenue TTM
2.06M
Revenue Per Share
0.01
Gross Profit TTM
0.36M
Debt / Equity
-
ROE
-161.37%
Net Debt
2.20M
ROCE
-25.63%
Diluted EPS TTM
-0.02

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-07-31 2023-07-31 2022-07-31 2022-03-31 2021-07-31
Type yearly yearly yearly yearly yearly
Date 2024-07-31 2023-07-31 2022-07-31 2022-03-31 2021-07-31
Income before tax -2.05M -2.39M -10.50M -10.50M -0.29M
Net income -2.05M -2.39M -10.50M -10.50M -0.29M
Selling general administrative 1.02M 1.72M 4.57M 4.57M 0.08M
Gross profit - - - - 0.00M
Reconciled depreciation 0.34M 0.30M 0.27M 0.27M 0.00M
Ebit - - -4.75M -4.75M -3.86M
Ebitda - - -10.16M -10.16M -0.08M
Operating income -0.90M -2.05M -4.75M -4.75M -0.08M
Interest expense 0.17M 0.15M 0.07M 0.07M 0.02M
Interest income 0.01M - - - 0.00M
Net interest income -0.16M -0.15M -0.07M -0.07M 0.00M
Total revenue 2.33M 1.03M 1.07M 1.07M 0.00M
Total operating expenses 3.23M 3.08M 5.82M 5.82M 0.08M
Cost of revenue - - - - 0.00M
Total other income expense net -0.99M -0.19M -5.68M -5.68M -0.21M
Net income from continuing ops -2.05M -2.39M -10.50M -10.50M -0.29M
Net income applicable to common shares - - -10.50M -10.50M -3.87M
Breakdown 2024-07-31 2023-07-31 2022-07-31 2022-03-31 2021-07-31
Type yearly yearly yearly yearly yearly
Date 2024-07-31 2023-07-31 2022-07-31 2022-03-31 2021-07-31
Total assets 4.51M 5.50M 6.32M 6.32M 2.20M
Other current assets - - - - 0.62M
Total liab 3.52M 3.75M 2.37M 2.37M 2.20M
Total stockholder equity 0.99M 1.75M 3.94M 3.94M -0.00M
Deferred long term liab - - - - 0.04M
Other current liab - - 0.18M 0.18M 0.06M
Common stock - - 22.80M 22.80M 13.79M
Capital stock 24.15M 22.84M 22.80M 22.80M 0.79M
Retained earnings -27.18M -25.13M -22.74M -22.74M -12.25M
Other assets - - - - 0.04M
Cash 0.37M 0.31M 0.73M 0.73M 0.12M
Total current liabilities 1.00M 2.79M 2.19M 2.19M 0.99M
Net debt 2.20M 2.42M 1.01M 1.01M 0.27M
Short long term debt 0.11M 1.80M 1.56M - 0.35M
Other stockholder equity - - 3.88M 3.88M 1.40M
Property plant equipment - - 5.30M 5.30M 3.05M
Total current assets 1.04M 0.44M 1.02M 1.02M 0.90M
Net tangible assets - - 3.94M 3.94M 2.94M
Net receivables - - 0.23M 0.23M 0.11M
Long term debt 2.47M 0.94M 1.74M 1.74M 0.06M
Accounts payable 0.22M 0.30M 0.17M 0.17M 0.30M
Non currrent assets other - 1.40M - - -
Non current assets total 3.47M 5.06M 5.30M 5.30M 0.00M
Capital lease obligations 0.08M 0.04M 0.00M - -
Breakdown 2024-07-31 2023-07-31 2022-07-31 2022-03-31 2021-07-31
Type yearly yearly yearly yearly yearly
Date 2024-07-31 2023-07-31 2022-07-31 2022-03-31 2021-07-31
Investments -0.08M -0.36M -2.09M -2.09M 0.03M
Change to liabilities - - -0.47M -0.47M 0.28M
Total cashflows from investing activities - - -2.09M -2.09M -0.04M
Net borrowings -0.23M - 1.21M 1.21M 0.29M
Total cash from financing activities 0.97M 1.04M 7.01M 7.01M 3.38M
Change to operating activities - - -0.03M -0.03M -0.56M
Net income -2.05M -2.39M -10.50M -10.50M -3.87M
Change in cash 0.06M -0.41M 0.58M 0.58M 0.09M
Begin period cash flow 0.31M 0.73M 2.17M 2.17M 0.07M
End period cash flow 0.37M 0.31M 0.73M 0.73M 2.17M
Total cash from operating activities -0.84M -1.10M -4.33M -4.33M -3.25M
Issuance of capital stock 1.21M 0.01M 6.07M 6.07M 0.18M
Depreciation 0.34M 0.30M 0.27M 0.27M 0.07M
Change to account receivables -0.12M - - - -0.08M
Sale purchase of stock - - 0.00M 0.00M -0.05M
Other cashflows from financing activities - - -0.29M -0.29M -0.25M
Change to netincome - - 6.40M 6.40M 0.83M
Capital expenditures 0.08M 0.36M 0.10M 0.10M 0.10M
Change in working capital -0.23M 0.50M -0.51M -0.51M 0.06M
Stock based compensation -0.02M 0.11M 0.90M 0.90M 0.02M
Other non cash items 0.13M 0.03M 2.79M 2.79M 0.86M
Free cash flow -0.92M -1.46M -4.43M -4.43M -0.21M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
SHRX
Sharp Therapeutics Corp.		 -
-%		 1.37 - - - 32.37 - -
NRX
NurExone Biologic Inc.		 -0.01
2.00%		 0.49 - 6.90 - 15.26 - -7.24
MIR
MedMira Inc		 -
-%		 0.06 - - 223.37 - 293.42 -80.03
TTI
Thiogenesis Therapeutics Corp.		 -
-%		 0.63 - - - 15.17 - -58.16

Profile*

Universal Ibogaine Inc

Universal Ibogaine Inc., a life sciences company, develops, acquires, and operates addiction treatment clinics in Canada. The company also undertakes planned clinical trial for research into the use of ibogaine for addiction treatment. Universal Ibogaine Inc. is headquartered in Calgary, Canada.

815 8th Avenue SW, Calgary, AB, Canada, T2P 3P2

855-426-4246

https://universalibogaine.com

Name Title Year Born
Dr. Alberto Sola Agullo M.D., Ph.D. Co-Founder, Pres & Director NA
Mr. Shayne Nyquvest Co-Founder NA
Mr. Greg J. Leavens C.A., CPA CFO & Corp. Sec. 1965
Mr. Nicholas Peter Karos CEO, Director of Capital Markets & Director NA
Ms. Colleen Clandening Director of Operations NA
Mr. Dugan Selkirk Mang. Communications & Investor Relations NA
Cathy Fernandes VP of Marketing & VP of Communications NA
Dr. Ian Rabb Chief Clinics Officer NA
Mr. Greg J. Leavens C.A., CPA CFO & Corporate Secretary 1965
Mr. Dugan Selkirk Manager Communications & Investor Relations NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…